Ascendis Pharma A/S (NASDAQ:ASND) Stock Rating Upgraded by StockNews.com

Ascendis Pharma A/S (NASDAQ:ASND - Get Free Report) was upgraded by equities researchers at StockNews.com from a "sell" rating to a "hold" rating in a research note issued to investors on Wednesday.

A number of other research analysts have also weighed in on ASND. Jefferies Financial Group lifted their price target on shares of Ascendis Pharma A/S from $174.00 to $196.00 and gave the company a "buy" rating in a research note on Tuesday, August 13th. Wedbush reiterated an "outperform" rating and issued a $181.00 price target on shares of Ascendis Pharma A/S in a research report on Friday, November 15th. JPMorgan Chase & Co. dropped their target price on Ascendis Pharma A/S from $180.00 to $174.00 and set an "overweight" rating for the company in a report on Wednesday, October 23rd. Oppenheimer reduced their price objective on Ascendis Pharma A/S from $190.00 to $180.00 and set an "outperform" rating for the company in a research report on Friday, November 15th. Finally, TD Cowen decreased their price objective on Ascendis Pharma A/S from $160.00 to $153.00 and set a "buy" rating on the stock in a research note on Friday, November 15th. Two research analysts have rated the stock with a hold rating and twelve have assigned a buy rating to the company's stock. According to MarketBeat, Ascendis Pharma A/S has a consensus rating of "Moderate Buy" and a consensus target price of $191.77.

Ascendis Pharma A/S Stock Performance

ASND stock traded down $0.06 during midday trading on Wednesday, reaching $124.38. 304,170 shares of the company traded hands, compared to its average volume of 451,370. The firm has a market capitalization of $7.54 billion, a price-to-earnings ratio of -15.40 and a beta of 0.66. Ascendis Pharma A/S has a 52-week low of $90.13 and a 52-week high of $161.00. The business has a 50 day moving average of $132.59 and a 200-day moving average of $132.38.

Ascendis Pharma A/S (NASDAQ:ASND - Get Free Report) last announced its quarterly earnings data on Tuesday, September 3rd. The biotechnology company reported ($2.05) EPS for the quarter, missing analysts' consensus estimates of ($1.54) by ($0.51). The business had revenue of $38.75 million for the quarter, compared to the consensus estimate of $94.74 million. Research analysts anticipate that Ascendis Pharma A/S will post -7.3 earnings per share for the current year.

Institutional Trading of Ascendis Pharma A/S

Several hedge funds and other institutional investors have recently bought and sold shares of the stock. Groupama Asset Managment purchased a new position in Ascendis Pharma A/S during the third quarter valued at $60,000. Price T Rowe Associates Inc. MD boosted its holdings in Ascendis Pharma A/S by 23.3% during the first quarter. Price T Rowe Associates Inc. MD now owns 1,781,926 shares of the biotechnology company's stock worth $269,374,000 after buying an additional 336,976 shares in the last quarter. Janus Henderson Group PLC raised its holdings in Ascendis Pharma A/S by 6.8% in the 3rd quarter. Janus Henderson Group PLC now owns 4,186,694 shares of the biotechnology company's stock valued at $625,075,000 after acquiring an additional 267,881 shares during the last quarter. Avoro Capital Advisors LLC raised its position in Ascendis Pharma A/S by 5.8% in the second quarter. Avoro Capital Advisors LLC now owns 4,196,661 shares of the biotechnology company's stock valued at $572,341,000 after purchasing an additional 229,995 shares during the period. Finally, Westfield Capital Management Co. LP boosted its position in shares of Ascendis Pharma A/S by 3.4% during the 3rd quarter. Westfield Capital Management Co. LP now owns 5,133,766 shares of the biotechnology company's stock worth $766,523,000 after acquiring an additional 170,942 shares in the last quarter.

About Ascendis Pharma A/S

Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates.